Screening and characterization of antiepileptic drugs with rapidly recurring hippocampal seizures in rats

[1]  J. Bruni,et al.  Valproic acid therapy for complex partial seizures. Its efficacy and toxic effects. , 1983, Archives of neurology.

[2]  J. Penry,et al.  Antiepileptic Drug Development: I. History and a Program for Progress , 1978, Epilepsia.

[3]  R. M. Joy,et al.  A pharmacological study in the kindling model of epilepsy , 1984, Neuropharmacology.

[4]  T. Albertson,et al.  Anticonvulsant drugs and their antagonism of kindled amygdaloid seizures in rats , 1980, Neuropharmacology.

[5]  L. Goodman,et al.  Comparative assays of antiepileptic drugs in mice and rats. , 1952, The Journal of pharmacology and experimental therapeutics.

[6]  C. Zorumski,et al.  Functional mapping of limbic seizures originating in the hippocampus: a combined 2-deoxyglucose and electrophysiologic study , 1985, Brain Research.

[7]  W. Löscher,et al.  Evidence for impaired GABAergic activity in the substantia nigra of amygdaloid kindled rats , 1985, Brain Research.

[8]  J. Perlin,et al.  Response properties of rapidly recurring hippocampal seizures in rats , 1988, Epilepsy Research.

[9]  D. Daly,et al.  Complex partial seizures and their treatment , 1976 .

[10]  B. Doane,et al.  The Limbic System: Functional Organization and Clinical Disorders , 1986 .

[11]  J. McNamara,et al.  The kindling model of epilepsy: a critical review. , 1985, CRC critical reviews in clinical neurobiology.

[12]  L. Brown,et al.  Anatomical correlates of electrical and behavioral events related to amygdaloid kindling , 1978, Annals of neurology.

[13]  J. Wada.  Pharmacological prophylaxis in the kindling model of epilepsy. , 1977, Archives of neurology.

[14]  R. Macdonald,et al.  Anticonvulsant drugs: mechanisms of action. , 1986, Advances in neurology.

[15]  M. Painter.  Antiepileptic Drugs, 2nd Edn edited by Dixon M. Woodbury, J. Kiffin Penry and C. E. Pippenger, Raven Press, 1982. $8.40 (xvii + 879 pages) ISBN 0 890 04498 8 , 1983, Trends in Neurosciences.

[16]  R. Baselt,et al.  Barbiturate serum levels and protection against kindled amygdaloid seizures in the rat , 1980, Neuropharmacology.

[17]  M. Parsonage.  Treatment with carbamazepine: adults. , 1975, Advances in neurology.

[18]  D. Callaghan,et al.  Pharmacological modification of amygdaloid-kindled seizures , 1980, Neuropharmacology.

[19]  E A Rodin,et al.  The Prognosis of Patients with Epilepsy , 1969, Journal of occupational medicine. : official publication of the Industrial Medical Association.

[20]  J. Perlin,et al.  Kindling with rapidly recurring hippocampal seizures , 1985, Brain Research.

[21]  W. Burnham,et al.  Development of a New Pharmacological Seizure Model: Effects of Anticonvulsants on Cortical‐and Amygdala‐Kindled Seizures in the Rat , 1980, Epilepsia.

[22]  H. Kupferberg,et al.  Comparative Anticonvulsant Activity and Neurotoxicity of Clobazam, Diazepam, Phenobarbital, and Valproate in Mice and Rats , 1982, Epilepsia.

[23]  P. Albright.  Effects of carbamazepine, clonazepam, and phenytoin on seizure threshold in amygdala and cortex , 1983, Experimental Neurology.

[24]  J. Penry,et al.  Antiepileptic Drug Development: II. Anticonvulsant Drug Screening , 1978, Epilepsia.

[25]  A. Delgado-Escueta,et al.  Basic mechanisms of the epilepsies : molecular and cellular approaches , 1986 .

[26]  W. Löscher,et al.  Is amygdala kindling in rats a model for drug-resistant partial epilepsy? , 1986, Experimental Neurology.

[27]  J. Perlin,et al.  Somatostatin augments the spread of limbic seizures from the hippocampus , 1987, Annals of neurology.

[28]  J. Cramer,et al.  Comparison of carbamazepine, phenobarbital, phenytoin, and primidone in partial and secondarily generalized tonic-clonic seizures. , 1985, The New England journal of medicine.

[29]  J. McNamara,et al.  Evidence implicating substantia nigra in regulation of kindled seizure threshold , 1984, The Journal of neuroscience : the official journal of the Society for Neuroscience.

[30]  F. Wilcoxon,et al.  A simplified method of evaluating dose-effect experiments. , 1948, The Journal of pharmacology and experimental therapeutics.

[31]  M. Iadarola,et al.  Substantia nigra: site of anticonvulsant activity mediated by gamma-aminobutyric acid. , 1982, Science.

[32]  R. Skelton,et al.  Kindling‐Related Changes in Afterdischarge “Thresholds” , 1976, Epilepsia.

[33]  R. C. Collins,et al.  Kainic acid induced limbic seizures: metabolic, behavioral, electroencephalographic and neuropathological correlates , 1981, Brain Research.

[34]  L. Goodman,et al.  Anticonvulsant properties of 5-phenyl-5-ethyl-hexahydropyrimidine-4,6-dione (mysoline), a new antiepileptic. , 1953, The Journal of pharmacology and experimental therapeutics.